Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
A potential sale of Legend Biotech may carry a 30% to 50% premium, which could generate up to 55.8 billion yuan for Genscript based on its 48% stake in the…
No Early Relief for JW Therapeutics from Cancer Wonder Drug
The biotech company logs revenue of 66 million yuan from its cutting-edge cancer therapy, but losses jump more than 50% to nearly 430 million yuan. Key Takeaways: JW Therapeutics prices…
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK -
Legend Holdings shows diversification isn’t always a winning formula
3396.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
